Trifluoroacetic acid → 9-(4-Fluoro-phenyl)-4-(3-tetrazol-1-yl-phenyl)-1,3-dihydro-benzo [b][1,4]diazepin-2-one
반응식
C(OC(=O)[NH:7][C:8]1[CH:13]=[CH:12][C:11](C2C=CC(F)=CC=2)=[CH:10][C:9]=1[NH:21][C:22](=[O:37])[CH2:23][C:24](=O)[C:25]1[CH:30]=[CH:29][CH:28]=[C:27]([N:31]2[CH:35]=[N:34][N:33]=[N:32]2)[CH:26]=1)(C)(C)C.[C:39](O)([C:41]([F:44])(F)F)=O>C(Cl)Cl>[F:44][C:41]1[CH:39]=[CH:10][C:9]([C:10]2[C:9]3[NH:21][C:22](=[O:37])[CH2:23][C:24]([C:25]4[CH:30]=[CH:29][CH:28]=[C:27]([N:31]5[CH:35]=[N:34][N:33]=[N:32]5)[CH:26]=4)=[N:7][C:8]=3[CH:13]=[CH:12][CH:11]=2)=[CH:8][CH:13]=1참가 물질
4
실험 절차
Prepared from {4′-fluoro-3-[3-oxo-3-(3-tetrazol-1-yl-phenyl)-propionylamino]-biphenyl-4-yl}-carbamic acid tert.-butyl ester (Example K56) by treatment with TFA in CH2Cl2 according to the general procedure M. Obtained as a light yellow solid (54 mg).